Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1-mutant Cholangiocarcinoma”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Ended earlyNCT05814536
What this trial is testing

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Who this might be right for
Cholangiocarcinoma With IDH1 MutationSolid Tumors With IDH1 Mutation
AnHeart Therapeutics Inc. 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Ended earlyNCT05921760
What this trial is testing

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Who this might be right for
IDH1-mutant Cholangiocarcinoma
Servier Bio-Innovation LLC 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03878095
What this trial is testing

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Who this might be right for
Malignant Solid NeoplasmRefractory CholangiocarcinomaRefractory Malignant Solid Neoplasm
National Cancer Institute (NCI) 24